IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.56
+1.11%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
Market Cap
$8.17B
MomentumView details →
1D Return
+1.11%
YTD Return
+53.45%
RSI (14)
37.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
Market Cap
$8.17B
RSI (14)
37.6
MomentumView details →
1D Return
+1.11%
YTD Return
+53.45%
SummaryUpdated Jun 1, 2026
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. The company went public in June 2019 and operates as a subsidiary of Roivant Sciences Ltd. Immunovant focuses on developing innovative monoclonal antibody treatments for autoimmune diseases, with its lead drug candidate batoclimab currently advancing through multiple Phase II clinical trials for various autoimmune conditions.
Similar companies
Latest newsMore news →
Immunovant, Inc. shares reached a new 52-week high of $43.89 during mid-day trading on Tuesday, last trading at $43.71 with a volume of 1,216,514 shares, after closing at $41.82.17d agoImmunovant, Inc. reported its Q1 2026 financial results, with a GAAP net loss of $153.2 million and diluted EPS of -$0.75.30d ago